JP2011515471A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011515471A5 JP2011515471A5 JP2011501845A JP2011501845A JP2011515471A5 JP 2011515471 A5 JP2011515471 A5 JP 2011515471A5 JP 2011501845 A JP2011501845 A JP 2011501845A JP 2011501845 A JP2011501845 A JP 2011501845A JP 2011515471 A5 JP2011515471 A5 JP 2011515471A5
- Authority
- JP
- Japan
- Prior art keywords
- gly
- asp
- pharmaceutical composition
- glu
- ala
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 116
- 108090000190 Thrombin Proteins 0.000 claims description 66
- 229960004072 thrombin Drugs 0.000 claims description 66
- 125000000539 amino acid group Chemical group 0.000 claims description 43
- 229920001184 polypeptide Polymers 0.000 claims description 40
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 40
- 239000012634 fragment Substances 0.000 claims description 25
- 210000004899 c-terminal region Anatomy 0.000 claims description 23
- 239000000556 agonist Substances 0.000 claims description 21
- 206010000891 acute myocardial infarction Diseases 0.000 claims description 16
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 150000001408 amides Chemical group 0.000 claims description 12
- 239000000539 dimer Substances 0.000 claims description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 10
- 235000004279 alanine Nutrition 0.000 claims description 10
- 150000001413 amino acids Chemical group 0.000 claims description 9
- 230000006907 apoptotic process Effects 0.000 claims description 9
- 239000004471 Glycine Substances 0.000 claims description 7
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 230000002107 myocardial effect Effects 0.000 claims description 7
- 108020002447 serine esterase Proteins 0.000 claims description 7
- 102000005428 serine esterase Human genes 0.000 claims description 7
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 6
- 208000010125 myocardial infarction Diseases 0.000 claims description 6
- 102000003790 Thrombin receptors Human genes 0.000 claims description 5
- 108090000166 Thrombin receptors Proteins 0.000 claims description 5
- 230000002861 ventricular Effects 0.000 claims description 5
- 102000007272 Apoptosis Inducing Factor Human genes 0.000 claims description 4
- 108010033604 Apoptosis Inducing Factor Proteins 0.000 claims description 4
- 108091036078 conserved sequence Proteins 0.000 claims description 4
- 235000018102 proteins Nutrition 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- 102000003952 Caspase 3 Human genes 0.000 claims description 2
- 108090000397 Caspase 3 Proteins 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 239000000203 mixture Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 68
- 235000001014 amino acid Nutrition 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 7
- 125000001931 aliphatic group Chemical group 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 239000003869 thrombin derivative Substances 0.000 description 4
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 3
- 125000002252 acyl group Chemical group 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- OXHYRVSBKWIFES-WWSDOYNLSA-N trap-14 peptide Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=CC=C1 OXHYRVSBKWIFES-WWSDOYNLSA-N 0.000 description 2
- FOVAPSHEBWJWGL-UHFFFAOYSA-N 1-[4-(3-chlorophenyl)-1-[3-(dimethylamino)propyl]piperidin-4-yl]propan-1-one;dihydrochloride Chemical compound Cl.Cl.C=1C=CC(Cl)=CC=1C1(C(=O)CC)CCN(CCCN(C)C)CC1 FOVAPSHEBWJWGL-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- IEHDJWSAXBGJIP-RYUDHWBXSA-N Phe-Val Chemical compound CC(C)[C@@H](C([O-])=O)NC(=O)[C@@H]([NH3+])CC1=CC=CC=C1 IEHDJWSAXBGJIP-RYUDHWBXSA-N 0.000 description 1
- 108010086780 arginyl-glycyl-aspartyl-alanine Proteins 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 210000005003 heart tissue Anatomy 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 108010084572 phenylalanyl-valine Proteins 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960003766 thrombin (human) Drugs 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7083708P | 2008-03-26 | 2008-03-26 | |
| US61/070,837 | 2008-03-26 | ||
| US13795308P | 2008-08-05 | 2008-08-05 | |
| US61/137,953 | 2008-08-05 | ||
| PCT/US2009/001954 WO2009142679A2 (en) | 2008-03-26 | 2009-03-26 | Methods for treating acute myocardial infarction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011515471A JP2011515471A (ja) | 2011-05-19 |
| JP2011515471A5 true JP2011515471A5 (enExample) | 2012-05-24 |
Family
ID=41170019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011501845A Pending JP2011515471A (ja) | 2008-03-26 | 2009-03-26 | 急性心筋梗塞を処置するための方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20110105400A1 (enExample) |
| EP (1) | EP2268304A2 (enExample) |
| JP (1) | JP2011515471A (enExample) |
| CA (1) | CA2719940A1 (enExample) |
| WO (1) | WO2009142679A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009229395A1 (en) | 2008-03-26 | 2009-10-01 | The Board Of Regents, The University Of Texas System | Method of treating degenerative diseases |
| EP3035942B1 (en) * | 2013-08-19 | 2022-12-14 | Schmidt, Klaus Michael | The non-anesthetic protective gas argon combination with liquid anesthetic agents for use in organ protection |
| US10220078B2 (en) | 2014-06-11 | 2019-03-05 | The Board Of Regents Of The University Of Texas System | Methods of using thrombin derivatives to treat medulloblastoma |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6630572B1 (en) * | 1986-10-31 | 2003-10-07 | The Board Of Regents, University Of Texas Syatems | Thrombin derived polypeptides: compositions and methods for use |
| US5352664A (en) * | 1986-10-31 | 1994-10-04 | Board Of Regents, The University Of Texas System | Thrombin derived polypeptides; compositions and methods for use |
| US5244460A (en) * | 1991-11-27 | 1993-09-14 | The United States Of America As Represented By The Department Of Health And Human Services | Method to foster myocardial blood vessel growth and improve blood flow to the heart |
| EP0886648B8 (en) * | 1995-06-07 | 2004-03-03 | Ortho Pharmaceutical Corporation | Compounds and peptides that bind to the erythropoietin receptor |
| ATE273322T1 (de) * | 1995-10-24 | 2004-08-15 | Chemo Sero Therapeut Res Inst | Tfpi-verwandte peptide die das wachstums von glatten muskelzellen inhibieren |
| US5912229A (en) * | 1996-03-01 | 1999-06-15 | Novo Nordisk Als | Use of a pharmaceutical composition comprising an appetite-suppressing peptide |
| US6197751B1 (en) * | 1997-11-10 | 2001-03-06 | The United States Of America As Represented By The Department Of Health And Human Services | Thymosin α1 promotes tissue repair, angiogenesis and cell migration |
| US6033436A (en) * | 1998-02-17 | 2000-03-07 | Md3, Inc. | Expandable stent |
| US20030130209A1 (en) * | 1999-12-22 | 2003-07-10 | Cheresh David A. | Method of treatment of myocardial infarction |
| US20040214836A1 (en) * | 1998-05-29 | 2004-10-28 | Cheresh David A. | Method of treatment of myocardial infarction |
| AU6411199A (en) * | 1998-10-13 | 2000-05-01 | Chiron Corporation | Angiogenically effective unit dose of fgf and method of administering |
| US6363938B2 (en) * | 1998-12-22 | 2002-04-02 | Angiotrax, Inc. | Methods and apparatus for perfusing tissue and/or stimulating revascularization and tissue growth |
| US20020063763A1 (en) * | 2000-11-29 | 2002-05-30 | Mantell David Allen | Apparatus and method for removing air bubbles from an ink jet printhead |
| TWI257307B (en) * | 2000-07-12 | 2006-07-01 | Orthologic Corp | Pharmaceutical composition for cardiac tissue repair |
| ATE254925T1 (de) * | 2000-07-19 | 2003-12-15 | Univ Texas | Stimulierung des knochenwachstums mit peptidderivaten von thrombin |
| CN1458974A (zh) * | 2000-07-20 | 2003-11-26 | 德克萨斯系统大学董事会 | 用非蛋白质水解激活的凝血酶受体的激动剂刺激软骨生长 |
| CN100509055C (zh) * | 2001-07-27 | 2009-07-08 | 奥索洛吉艾斯有限公司 | 使用凝血酶衍生的缩氨酸治疗慢性真皮溃疡 |
| CA2511223A1 (en) * | 2002-01-16 | 2003-07-31 | The Board Of Regents, The University Of Texas System | Thrombin derived peptides for promoting cardiac tissue repair |
| AU2003256343B2 (en) * | 2002-07-02 | 2006-12-21 | Orthologic Corp. | Thrombin peptide derivatives |
| EP1539800B1 (en) * | 2002-07-02 | 2007-05-23 | Orthologic Corp. | Thrombin peptide derivative dimers |
| ITRM20030178A1 (it) * | 2003-04-17 | 2004-10-18 | Sigma Tau Ind Farmaceuti | Uso della l-carnitina per il trattamento di patologie cardiovascolari. |
| DE602004005564T2 (de) * | 2003-12-31 | 2007-12-13 | Orthologic Corp., Tempe | Pharmazeutische Zusammensetzung für Thrombinpeptidderivaten |
| US20060287234A1 (en) * | 2005-06-17 | 2006-12-21 | Genentech, Inc. | Wound healing |
| CA2663547C (en) * | 2006-09-22 | 2020-08-25 | Orthologic Corp. | Method of treating endothelial dysfunction |
| WO2008124172A1 (en) * | 2007-04-10 | 2008-10-16 | The Board Of Regents, The University Of Texas System | Combination therapy for chronic dermal ulcers |
| EP2155236A1 (en) * | 2007-04-10 | 2010-02-24 | The Board of Regents,The University of Texas System | Combination therapy for cardiac revascularization and cardiac repair |
| US20110117075A1 (en) * | 2008-03-26 | 2011-05-19 | Orthologic Corp. | Thrombin derived peptides for smooth muscle relaxation |
-
2009
- 2009-03-26 EP EP09750910A patent/EP2268304A2/en not_active Withdrawn
- 2009-03-26 WO PCT/US2009/001954 patent/WO2009142679A2/en not_active Ceased
- 2009-03-26 CA CA2719940A patent/CA2719940A1/en not_active Abandoned
- 2009-03-26 JP JP2011501845A patent/JP2011515471A/ja active Pending
- 2009-03-26 US US12/934,585 patent/US20110105400A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102285378B1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 | |
| RU2678134C2 (ru) | Конъюгаты инсулин-инкретин | |
| JP4026854B2 (ja) | 腸栄養性ｇｌｐ―２ペプチドのアンタゴニスト | |
| JP5986550B2 (ja) | Ｎ末端において修飾されたグルコース依存性インスリン分泌刺激ポリペプチド（ｇｉｐ）のアナログ | |
| AU2021278157A1 (en) | Dual-agonist compound for both GLP-1 and GIP receptors and application thereof | |
| JP2013518115A5 (enExample) | ||
| KR102052983B1 (ko) | 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도 | |
| JP2014508510A5 (enExample) | ||
| KR20190072615A (ko) | 신경펩티드 y 수용체의 조절제로서의 사이클릭 펩티드 티로신 티로신 화합물 | |
| WO2010013012A2 (en) | Novel polypeptides and uses thereof | |
| JP2018538356A5 (enExample) | ||
| CN110114065A (zh) | 通过甲状旁腺激素受体刺激进行的骨折靶向性骨再生 | |
| JP2005053930A5 (enExample) | ||
| RS65983B1 (sr) | Postupci i kompozicije za lečenje kancera | |
| KR102714599B1 (ko) | Npra 작용제, 조성물 및 이의 용도 | |
| LV12293B (en) | Parathyroid hormone analogues for the treatment of osteoporosis | |
| CN114026114B (zh) | 用于治疗再灌注损伤的bnip3肽 | |
| KR102700862B1 (ko) | apoC-II 모방 펩타이드 | |
| JP2011515471A5 (enExample) | ||
| JP2003073400A (ja) | 骨形成作用を有する新規なペプチドおよびこれを固定化してなる骨形成促進剤 | |
| US20110195900A1 (en) | Peptidic pth receptor agonists | |
| KR101345253B1 (ko) | 하나 이상의 합성 아미노산 치환을 가지는 뉴로펩타이드 ｙ 유사체 | |
| CA2719940A1 (en) | Methods for treating acute myocardial infarction | |
| KR102520348B1 (ko) | 페길화 생활성 펩타이드 및 그의 용도 | |
| WO1998026070A1 (en) | Bone stimulating factor |